Japan-based Taiho Pharmaceutical Co., Ltd. and Araris Biotech AG, a Swiss biotechnology company developing next-generation antibody drug conjugates (ADCs), entered into a definitive agreement pursuant to which Taiho Pharmaceutical will fully acquire Araris. Taiho Pharmaceutical will pay USD 400 million at closing, with the potential for additional milestone payments of up to USD 740 million..

总部位于日本的 Taiho Pharmaceutical Co., Ltd. 与开发下一代抗体药物偶联物 (ADC) 的瑞士生物技术公司 Araris Biotech AG 达成了一项最终协议，根据该协议，Taiho Pharmaceutical 将全面收购 Araris。Taiho Pharmaceutical 将在交易结束时支付 4 亿美元，并可能额外支付高达 7.4 亿美元的里程碑款项。

Araris

阿拉里斯

is a spin-off company of the Paul-Scherrer-Institute in Switzerland and pioneering the development of best-in-class ADCs with superior design, high linker solubility and simple manufacturing that address the shortcomings of current generation ADCs. ADCs are designed to selectively deliver cytotoxic drugs (payloads) to cancer cells by attaching them to antibodies that bind specifically to cancer cells through linkers.

是一家从瑞士保罗谢尔研究所分离出来的公司，致力于开发具有卓越设计、高连接子溶解性和简单制造工艺的顶级抗体偶联药物（ADC），以解决当前ADC的不足之处。ADC通过连接子将细胞毒性药物（有效载荷）附着在特异性结合癌细胞的抗体上，从而实现选择性地将药物递送至癌细胞。

Foundational to Araris’ approach is its novel, proprietary ADC linker platform AraLinQ. This platform has generated highly uniform, stable and potent ADC therapeutic candidates that have demonstrated a wider range of safety and increased antitumor effect compared to conventional ADCs in preclinical studies.

Araris的方法的基础是其新颖的、专有的ADC连接子平台AraLinQ。该平台生成了高度均匀、稳定且有效的ADC治疗候选药物，在临床前研究中显示出比传统ADC更广泛的安全性和增强的抗肿瘤效果。

.

。

The acquisition takes places ahead of first clinical trials. Araris is advancing three products for the treatment of hematological and solid tumors developed using its unique AraLinQ technology, which are currently in the preclinical stage. These products are anticipated to enter into clinical trials between 2025 and 2026.

收购在首次临床试验之前进行。Araris正在推进三种用于治疗血液和实体肿瘤的产品，这些产品是利用其独特的AraLinQ技术开发的，目前处于临床前阶段。预计这些产品将在2025年至2026年之间进入临床试验。

By acquiring Araris' innovative ADC drug discovery technology platform, Taiho Pharmaceutical will further expand its ongoing development portfolio in the field of oncology..

通过收购 Araris 创新的 ADC 药物发现技术平台，大鹏制药将进一步扩大其在肿瘤学领域的持续开发组合。

The acquisition follows a research collaboration between

该收购遵循了之间的研究合作

Taiho Pharmaceutical

大鹏制药

and Araris signed in November 2023. Masayuki Kobayashi, President and Representative Director of Taiho Pharmaceutical commented, “We are very pleased to have entered into this agreement with Araris. AraLinQ is an innovative technology that enables next-generation ADC drug discovery. We are confident that the addition of Araris' knowledge, experience and technology platform in ADC drug discovery, as well as its development pipeline, will lead to further expansion and strengthening of Taiho's drug discovery capabilities and portfolio.

2023年11月签署。大鹏制药公司总裁兼代表董事小林正幸评论道：“我们非常高兴与Araris达成该协议。AraLinQ 是一项创新技术，能够实现下一代ADC药物的发现。我们相信，结合Araris在ADC药物研发方面的知识、经验和技术平台，以及其开发管线，将进一步拓展和强化大鹏的药物研发能力和产品组合。”

Going forward, together with Araris, we will strive to develop innovative drugs that can contribute to patients globally.”.

今后，我们将与Araris共同努力，开发能为全球患者作出贡献的创新药物。”

Dragan Grabulovski, CEO and Co-founder of Araris commented, “Araris’ unique ADC technology represents a quantum leap for the ADC field, potentially offering precise payload delivery of multiple mechanisms of action simultaneously to the tumor, with less toxicity. We are proud to combine with Taiho, our partner since November 2023, whose significant cancer expertise will support us in turbo-charging the clinical development of our potent ADC candidates in hematological and solid tumors.”.

德拉甘·格拉布洛夫斯基（Dragan Grabulovski），Araris首席执行官兼联合创始人评论道：“Araris独特的ADC技术代表了ADC领域的一项重大飞跃，有望以更低的毒性同时将多种作用机制的载荷精准递送至肿瘤。我们很自豪能与自2023年11月以来的合作伙伴Taiho携手，他们深厚的癌症领域专业知识将帮助我们加速推进在血液肿瘤和实体瘤中高效ADC候选药物的临床开发。”

Dima Kuzmin, Managing Partner of 4BIO Capital and Chairman of Araris, added: “This acquisition validates Araris’ position as one of the most exciting ADC companies in the market. Having worked with Araris closely during its collaboration, Taiho knows the potential of Araris’ proprietary AraLinQ technology and is best placed to accelerate these transformative treatments to patients.”.

4BIO资本的管理合伙人、Araris的董事长德米亚·库兹明补充道：“此次收购证实了Araris作为市场上最令人兴奋的ADC公司之一的地位。在与Araris密切合作期间，大鹏制药深知Araris专有的AraLinQ技术的潜力，并且最有能力加速这些变革性治疗手段惠及患者。”

With the acquisition, Araris will become a wholly owned subsidiary of Taiho Pharmaceutical and will continue its business, research and development activities at its current location in Zurich, Switzerland. Following necessary procedures, the Acquisition is expected to be completed in first half of 2025..

通过此次收购，Araris将成为大鹏制药的全资子公司，并将继续在瑞士苏黎世的现址开展业务、研发活动。在完成必要程序后，预计收购将于2025年上半年完成。

Founded in 2019, Araris a spin-off company of the Paul-Scherrer-Institute (part of ETH domain) in Switzerland, with Dr. Philipp Spycher, Dr. Isabella Attinger-Toller and Dr. Dragan Grabulovski among its founders. Araris’ investors include 4BIO Capital, b2venture, Pureos Bioventures, Redalpine, Schroders Capital, VI Partners, Wille AG, Institute for Follicular Lymphoma Innovation and Samsung Ventures..

Araris成立于2019年，是瑞士保罗谢尔研究所（隶属于ETH领域）的衍生公司，其创始人包括菲利普·施皮歇博士、伊莎贝拉·阿廷格-托勒博士和德拉甘·格拉布洛夫斯基博士。Araris的投资方包括4BIO Capital、b2venture、Pureos Bioventures、Redalpine、Schroders Capital、VI Partners、Wille AG、滤泡性淋巴瘤创新研究所和三星风险投资。

(Press release / SK)

（新闻稿 / SK）

0

0

Comments

评论

Back to all news

返回所有新闻

Please

请

login

登录

or

或

sign up

注册

to comment.

评论。

Commenting guidelines

评论指南

Send

发送